Home » Stocks » RZLT

Rezolute, Inc. (RZLT)

Stock Price: $6.55 USD 0.14 (2.18%)
Updated May 12, 2021 1:45 PM EDT - Market closed
Market Cap 53.54M
Revenue (ttm) n/a
Net Income (ttm) -19.30M
Shares Out 8.05M
EPS (ttm) -3.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $6.55
Previous Close $6.41
Change ($) 0.14
Change (%) 2.18%
Day's Open 6.45
Day's Range 6.40 - 6.93
Day's Volume 27,588
52-Week Range 6.05 - 21.11


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcomi...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.

3 months ago - GlobeNewsWire

RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of...

4 months ago - GlobeNewsWire

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name ... [Read more...]

Nevan Elam
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Rezolute stock is "Buy." The 12-month stock price forecast is 31.50, which is an increase of 380.92% from the latest price.

Price Target
(380.92% upside)
Analyst Consensus: Buy